NervGen Pharma Corp. Common stock
NGEN Real Time Price USDRecent trades of NGEN by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Ro Khanna House / D | Sale $1,001 - $15,000 | Mar 24, 2020 |
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NGEN holdings by institutional investors
Quarterly net insider trading by NGEN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$50,000 Jul 10, 2026 Issue: Veterans Defense Health Issues
-
$50,000 Apr 08, 2026 Issue: Veterans Defense Health Issues
-
$50,000 Jan 07, 2026 Issue: Veterans Defense Health Issues
-
$30,000 Oct 14, 2025 Issue: Veterans Defense Health Issues
Former government officials who have lobbied for NGEN
5 former government officials at 1 lobbying firm have lobbied for NGEN, most recently Jul 10, 2026.
-
Susan Sweat Congress LC, LA & LD House Office (Wicker); LD Senate Member Office (Wicker)
-
Ashley Palmer Congress New Dep Asst Sec, Cong. Affairs, HHS; Prof Staff Mem, Senate Approp Cmte;Sr Policy Advisor, Coalitions and Mem Services Svcs Aide, HouseBudget Cmte; Sr Leg Assistant, Leg Asst, House Mem Office (Boehner);Leg Asst, Staff Asst, House Mem Office (Putnam)
-
Christopher Hodgson House New Legislative Assistant (Scalise), Floor Assistant & Deputy Floor Director for House Majority Whip (Scalise), Deputy Director & Director of Legislative Affairs (Pence)
-
William Smith Congress Staff Director, House Approps Cmte; Deputy Staff Director, House Approps Cmte; Chief of Staff, Legislative Director, Senior Legislative Assist, House Member Office (Rogers); Staff Assistant, Senate Approps Cmte
-
Anthony Lazarski Senate Senior Legislative Advisor, Senate Member Office (Inhofe); Professional Staff Member, Senate Armed Services Committee; Military Legislative Assistant, Senate Member Office (Inhofe)
NGEN Estimated quarterly lobbying spending
NGEN Revenue by Segment or Geography
New NGEN patent grants
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NGEN from public contracts
Recent insights relating to NGEN
Recent picks made for NGEN stock on CNBC
ETFs with the largest estimated holdings in NGEN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NGEN stock a Buy, Sell, or Hold?
- What is the price target for $NGEN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NGEN stock?
- Who owns the most shares of $NGEN stock?
- What funds own $NGEN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NGEN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
NervGen Pharma Corp. Common stock (NGEN) Historical Stock Prices
Daily open, high, low, close, adjusted close and volume for NervGen Pharma Corp. Common stock (NGEN).
Quiver Premium charts NGEN's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.
Upgrade to Premium| Date | Open | High | Low | Close | Adj. Close | Volume |
|---|
Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.
The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.
Explore the Quiver APIWe estimate that -- received a compensation of -- in --, making them the highest paid executive at NGEN, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|